Chelsea Therapeutics International Ltd.
(NASDAQ : CHTP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
1.15%302.831.4%$587.71m
AMGNAmgen, Inc.
0.19%233.861.3%$518.92m
GILDGilead Sciences, Inc.
1.87%67.161.0%$370.38m
REGNRegeneron Pharmaceuticals, Inc.
1.03%372.122.6%$303.57m
VRTXVertex Pharmaceuticals, Inc.
-0.04%222.981.9%$268.01m
ILMNIllumina, Inc.
2.26%327.053.5%$238.37m
ARWRArrowhead Pharmaceuticals, Inc.
3.02%67.5112.0%$192.87m
EXASEXACT Sciences Corp.
3.56%86.5924.0%$184.80m
CLVSClovis Oncology, Inc.
11.48%9.8814.7%$180.78m
ALXNAlexion Pharmaceuticals, Inc.
5.48%113.312.0%$179.46m
SRPTSarepta Therapeutics, Inc.
-0.29%109.6514.6%$148.41m
AAgilent Technologies, Inc.
0.68%82.081.6%$141.44m
BMRNBioMarin Pharmaceutical, Inc.
0.75%80.684.3%$131.07m
SGENSeattle Genetics, Inc.
0.43%117.666.1%$128.43m
NBIXNeurocrine Biosciences, Inc.
-0.43%115.985.0%$127.01m

Company Profile

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), and related conditions and diseases along with its development of prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease and cancer. As of December 31, 2009, it was focused on its drug development resources on two clinical stage development projects: droxidopa for symptomatic NOH and other potential indications, and its portfolio of non-metabolized antifolate compounds for the treatment of rheumatoid arthritis.